Latest Clostridium Stories
GREENSBORO, N.C., April 14, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC, maker of XEOMINÂ® (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, today announced the launch of the "Make Your Mark" campaign.
FRANKFURT, Germany, April 12, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that results from sub-group analyses of a prospective, repeated dose, double-blind study evaluating the long-term safety and efficacy of XEOMINÂ® (incobotulinumtoxinA), a botulinum toxin type A free from accessory (complexing) proteins, will be presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii, U.S.
LYNBROOK, N.Y., April 11, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp.
MALVERN, Pa., April 11, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc.
SUNNYVALE, Calif., April 11, 2011 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its XpertÂ® C. difficile/Epi test. Cepheid's first Xpert C.
Clostridium difficile can lead to diarrhea, colitis SILVER SPRING, Md., April 8, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today cleared a test called the Cepheid Xpert C.
SAN DIEGO, April 5, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that NASDAQ has halted trading of the Company's common stock this morning. The Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S.
SAN DIEGO, April 2, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
DISPATCHÂ® Towels with Bleach have the fastest EPA registered kill time for Clostridium difficile OAKLAND, Calif., March 30, 2011 /PRNewswire/ -- The Clorox Company (NYSE: CLX) announced today that the U.S.
GREENSBORO, N.C., March 30, 2011 /PRNewswire/ -- Merz Pharmaceuticals, LLC announced today that the Centers for Medicare and Medicaid Services (CMS) has granted a unique Healthcare Common Procedure Coding System (HCPCS) billing code, Q2040, for XeominÂ® (incobotulinumtoxinA).
Clostridium botulinum is a gram-positive, rod-shaped bacterium that produces neurotoxins, known as botulinum neurotoxins types A-G, that cause the flaccid muscular paralysis seen in botulism. It is the main paralytic agent in botox and is commonly found in soil. It is also an obligate anaerobe, meaning oxygen is poisonous to the cells. Superoxide dismutase helps C. botulinum tolerate traces of oxygen. It was first recognized and isolated in 1895 by Emile van Ermengem. Subsequent outbreaks...
- One of a pair of round metal cymbals attached to the fingers and struck together for rhythm and percussion in belly dancing.